Cerebrovascular Disease and Statins

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Elevated low-density lipoprotein-cholesterol (LDL-C) is a primary driver of atherosclerotic cardiovascular disease (ASCVD).
• Stroke represents a significant cause of mortality and acquired disability, posing a major public health challenge.
• Statins are central to ASCVD management due to their lipid-lowering and potential pleiotropic effects.

Purpose of the Study:

• To review the evidence, clinical use, and recommendations for statins in stroke prevention.
• To explore the role of statins in various stroke subtypes and related neurological conditions.
• To discuss the efficacy of statins in both primary and secondary stroke prevention strategies.

Main Methods:

• Literature review of epidemiological studies and clinical trials, including the SPARCL trial.
• Analysis of statin intervention studies focusing on cardiovascular events and stroke risk.
• Discussion of evidence pertaining to statins in acute stroke phases, different stroke etiologies, and cognitive function.

Main Results:

• Statin intervention studies demonstrate a reduced risk of stroke in patients with atherosclerosis.
• The SPARCL trial confirmed atorvastatin's benefit in secondary prevention of ischemic stroke.
• Statins contribute to decreased cardiovascular events in post-stroke patients.

Conclusions:

• Statins are crucial for managing LDL-C and preventing ASCVD, including stroke.
• Evidence supports statin use for both primary and secondary stroke prevention.
• Further research is needed to clarify statin roles in specific stroke types and cognitive impairment.